Sanjai Rao, MD

  • 11Articles
  • 49.2KReads
  • 2008–2023Active
  • 11Collaborators
  • 184Citations

About

Sanjai Rao, MD, is affiliated with the University of California San Diego and VA San Diego Healthcare System. Rao has published extensively on schizophrenia and schizoaffective disorders, focusing on treatment landscapes, therapy sequencing, adverse events, treatment adherence, cognitive impairment, and recovery definitions. Additional work includes research on depression, particularly augmentation strategies for suicidal ideation and insights from the STAR*D trial. Rao’s publications span from 2008 to 2023 in Psychiatrist.com journals.

Publications

JCP
The Emerging Treatment Landscape in Schizophrenia
Commentary

The Emerging Treatment Landscape in Schizophrenia

January 18, 2023

This article provides an overview of emerging therapies poised to transform the treatment paradigm for patients with living with schizophrenia.
,
JCP
Adverse Events and Treatment Adherence in Schizophrenia
Commentary

Adverse Events and Treatment Adherence in Schizophrenia

January 18, 2023

This article examines the effects of treatment-related adverse events on adherence to medication and strategies to improve adherence in practice.
,
JCP
The Epidemiology and Global Burden of Schizophrenia
Commentary

The Epidemiology and Global Burden of Schizophrenia

January 18, 2023

This article explores the costs and burden of schizophrenia and provides an overview of disease prevalence, incidence, and trends over time.
,
JCP
Optimizing Therapy Selection, Sequencing in Schizophrenia
Commentary

Optimizing Therapy Selection, Sequencing in Schizophrenia

January 18, 2023

This article summarizes the current treatment landscape in schizophrenia, along with contexts in which agents should be prescribed.
,
JCP
Defining and Achieving Treatment Recovery in Schizophrenia
Commentary

Defining and Achieving Treatment Recovery in Schizophrenia

January 18, 2023

This article defines treatment recovery in schizophrenia and summarizes strategies clinicians can pursue to improve patient outcomes.
,
JCP
Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video
Insights

Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video

January 14, 2023

Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...
,
JCP
Treating Schizophrenia: Side Effects and Adherence Video
Insights

Treating Schizophrenia: Side Effects and Adherence Video

January 14, 2023

One of the central gaps that can affect treatment adherence for individuals with schizophrenia is side effects. Adverse events can lead to substantial impacts across all aspects of daily...
JCP
Sequencing Therapy in the Treatment of Schizophrenia Video
Insights

Sequencing Therapy in the Treatment of Schizophrenia Video

January 14, 2023

Balancing and optimizing safety and efficacy when treating patients with schizophrenia can be challenging. New approaches to treatment may impact symptoms more effectively and contribute to better adherence. Sequencing,...
JCP
Shared Decision Making in Schizophrenia Treatment Video
Insights

Shared Decision Making in Schizophrenia Treatment Video

January 14, 2023

Although there are now multiple medications available to treat schizophrenia, many gaps still exist as a barrier to treatment success resulting in lower quality of life for this patient...
,
JCP
Original Research

Augmentation With Citalopram for Suicidal Ideation in Middle-Aged and Older Outpatients With Schizophrenia and Schizoaffective Disorder Who Have Subthreshold Depressive Symptoms: A Randomized Controlled Trial

March 9, 2010

, , , et al
JCP
ASCP Corner

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Lessons Learned

July 31, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe